Clinical Data We observed that two-thirds of patients in each disease cohort achieve a 6-month or longer treatment-free interval at the one-year mark – 66% of wet AMD patients, 69% of DME patients and 66% of RVO patients," said Jason Ehrlich, M.D., Ph.D., Chief Medical Officer at Kodiak Sciences. "Moreover, 78% of wet AMD patients and 84% of DME patients were on a 4-month or longer interval at Year 1, as were 75% of RVO patients. Said differently, an average of only 2.0, 1.0, and 1.7 retreatments were given in the ten months following the three loading doses in AMD, DME, and RVO patients respectively. Remarkably, 54% of wet AMD patients required only one retreatment and 50% of DME patients required no retreatment in Year 1.""We are seeing strong anti-VEGF efficacy for KSI-301, when we look to historical data for anti-VEGFs and new late-stage trial data presented at today's meeting," continued Dr. Ehrlich. "In wet AMD, we observed a mean 5.7 letter improvement, to 69.7 ETDRS eye chart letters (~20/40 Snellen) at Year 1. In DME, we observed a mean 7.6 letter improvement to 73.9 eye chart letters (~20/32 Snellen) at Year 1, and in RVO we observed a mean 22.2 letter improvement to 76.6 letters (~20/32 Snellen). We also remain pleased with the safety profile of KSI-301, now with over 700 doses given in the Phase 1b study and over 2,000 administered across the ongoing KSI-301 clinical development program."